Roundtable Roundup: Relapsed CLL After 2 Prior Lines Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases Managing Intermediate-Risk Myelofibrosis With Ruxolitinib Peers Evaluate CAR T Referral and Bridging Process for Early Relapsed Multiple Myeloma Brunner Discusses Dosing Approaches for...
its efficacy should be confirmed in the context of second-generation Bruton tyrosine kinase inhibitors, concluded the team. Still, based on their current results, they suggest that patients who fall into the high-risk category should be the top candidates considered for combination therapies and/or ...